الفهرس 
Introduction and Aim of workOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
NHL accounts for about 19.7 cases of NHL per 100,000 adults per year, 6.3 deaths per 100,000 adults per year. About 2.1 percent of men and women are diagnosed with NHL at some point during their lifetime, and there were around 530,919 people living with non-Hodgkin lymphoma. Globally, as of 2010, there were 210,000 deaths. Globally, up from 143,000 in 1990, so it was important to study risk factors implicated in disease development and prognosis.
Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), was originally described as an endothelial cell-specific mitogen
VEGF is produced by many cell types including tumor cells, macrophages, platelets, keratinocytes, and renal mesangial cells. The activities of VEGF are not limited to the vascular system; VEGF plays a role in normal physiological functions such as bone formation, hematopoiesis and wound healing.
The VEGF family comprises in mammals five members: VEGF-A, placenta growth factor (PGF), VEGF-B, VEGF-C and VEGF-D. The latter ones were discovered later than VEGF-A, and, before their discovery, VEGF-A was called just VEGF. A number of VEGF-related proteins encoded by viruses (VEGF-E) and in the venom of some snakes (VEGF-F) have also been discovered.
The VEGF gene is located on chromosome 6p21.3 and consists of 8 exons with alternate splic¬ing, forming a family of proteins. At least 30 single nucleotide polymor¬phisms (SNPs) in this gene have been described. Several transcription factor-binding sites are found in the VEGF 5’-untranslated region (UTR), and variation within this region increases transcriptional activity. Polymorphisms within the 5’-UTR lead to differences in VEGF expression between individuals and may influence the etiology of a variety of pathological conditions with which VEGF has been associated.
VEGF gene polymorphism is associated with different diseases such as osteoarthritis, chronic myleomonocytic leukemia, acute myelogenous leukemia, multiple myeloma, lung carcinomas, breast carcinomas, non hodgkin lymphomas, melanoma.
The aim of our study was to detect VEGF gene polymorphism by PCR – RFLP method in 40 NHL patients to identify gene relation to clinical features and laboratory findings at diagnosis, and its correlation with disease progression and outcome in NHL patients.
Conclusion and recommendations:
The VEGF gene polymorphism is not associated with NHL development, diagnosis, survival or response to treatment.
we recommend that these results must be verified by further studies with larger patient populations as well as larger control population for better understanding of the functional consequences of VEGF in NHL patients.